Project Details
Description
7. PROJECT SUMMARY/ABSTRACT
The Centers of Excellence in Regulatory Science and Innovation (CERSI) program allows the U.S. Food and
Drug Administration (FDA) to form extramural partnerships that foster robust and innovative research to
develop new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of FDA-
regulated products, supporting regulatory decision-making and the overall mission of the FDA. Over the past
seven years, the Yale-Mayo Clinic CERSI has pursued a series of innovative research projects that leverage
real-world data sources to assess the safety, efficacy, quality, and performance of FDA-regulated products,
informing regulatory decision-making as well as manufacturers, clinicians, and patients in support of optimizing
patient-centered care, along with providing and supporting high-quality mentorship and training in regulatory
science. The Yale-Mayo Clinic CERSI will continue this work, conducting high-quality, high-impact regulatory
science research in priority areas identified by the FDA to modernize development and evaluation of FDA-
regulated products, strengthen post-market surveillance and labelling of FDA-regulated products, and
invigorate public health preparedness and response of FDA, patients, and consumers. Over the 5-year award,
the Yale-Mayo Clinic CERSI will pursue the following specific aims:
Specific Aim 1. Strengthen existing extramural partnerships between FDA and the Yale-Mayo Clinic CERSI,
bridging the campuses of Yale University and Mayo Clinic, and create and foster new relationships that support
the FDA's regulatory mission.
Specific Aim 2. Conduct high-quality, high-impact regulatory science in collaboration with FDA to develop new
tools, standards, and approaches that provide timely assessments of the safety, efficacy, quality, and
performance of FDA-regulated products, thereby supporting regulatory decision-making.
Specific Aim 3. Provide and support high-quality mentorship and training in regulatory science at Yale
University and Mayo Clinic, strengthening regulatory science at both institutions through educational efforts
and scientific exchange with FDA scientists and across the CERSI network.
Specific Aim 4. Foster collaboration among the Yale-Mayo Clinic CERSI, the CERSI network, FDA, industry
and other key stakeholders, including pursuit of non-federal funding to better leverage FDA-related
opportunities and support the CERSI program.
Status | Active |
---|---|
Effective start/end date | 9/1/21 → 8/31/25 |
Funding
- U.S. Food and Drug Administration: $511,963.00
- U.S. Food and Drug Administration: $432,943.00
- U.S. Food and Drug Administration: $347,000.00
- U.S. Food and Drug Administration: $104,255.00
- U.S. Food and Drug Administration: $2,021,987.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.